跳至主要内容
临床试验/NCT05802810
NCT05802810已完成1 期

The Mass Balance Study of [14C]JT001 in Chinese Healthy Adult Male Subjects

Shanghai Vinnerna Biosciences Co., Ltd.1 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2023年3月18日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
7
试验地点
1
主要终点
cumulative excretion rate of total radioactive material in fecal matter

研究概览

简要总结

This study is a single center, single dose, non-randomized, open design clinical study.By quantitative analysis of the biological samples of subjects after oral administration of [14C]JT001, the data of human radioactive excretion rate and the main excretion pathway will be obtained. The main metabolites ,metabolic pathways and elimination pathways of JT001 will be identified.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy adult males
  • Age: 18-45 years old
  • Body weight: Body mass index (BMI) is between 19.0 and 26.0 kg/m2 (including boundary values), and the body weight of the subject is not less than 50.0 kg;
  • Voluntarily sign informed consent;
  • Subjects were able to complete the trail according to protocol.

排除标准

  • Physical examination, vital signs, routine laboratory examination, imaging examination abnormal and clinically significant
  • The electrocardiogram was abnormal and was considered clinically significant by the investigators, or has a history of organic heart disease
  • Has hepatitis B (HBV) or hepatitis C (HCV) or HIV antibody and syphilis antibody positive;
  • Any drug that inhibits or induces the drug transporters P-gp and BCRP has been used within 30 days prior to the screening period
  • Any conditions that may affect drug absorption.
  • Previous antineoplastic therapy meets washout requirements.
  • Hemorrhoids or perianal disease with regular/ongoing blood in the stool, irritable bowel syndrome, inflammatory bowel disease
  • Habitual constipation or diarrhea.
  • Significant radioactive exposure within 1 year.

研究组 & 干预措施

[14C]JT001

Experimental

干预措施: [14C]JT001 (Drug)

结局指标

主要结局

cumulative excretion rate of total radioactive material in fecal matter

时间窗: 1 month

After oral administration of the drug, the subjects collected feces for 10 Days to obtain the excretion of accumulated radioactive substances in feces

time to peak(Tmax)

时间窗: 1 month

After a single dose, the time of peak blood concentration

Total radioactive recovery

时间窗: 1 month

The percentage of radioactivity recovered from collected samples

Peak concentration(Cmax)

时间窗: 1 month

The highest plasma drug concentration that can be achieved after medication

elimination half life(t1/2)

时间窗: 1 month

the time it takes the blood to reduce the concentration of the drug to half

Major metabolites in human plasma, urine, and feces by liquid chromatography-mass spectrometry (LC-MS/MS)

时间窗: 1 month

The main metabolites in plasma, urine and fecal samples will be identified by liquid chromatography-mass spectrometry (LC-MS/MS)

次要结局

  • Adverse events (AEs)(2 month)

研究者

发起方
Shanghai Vinnerna Biosciences Co., Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

The Mass Balance Study of [14C]JT001 | 临床试验